Guanfacine Tablet, Extended Release
Product Images NDC 51407-953

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 51407-953). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-952-01ol (Guanfacine ER Tablets USP 1mg)

Label for GUANFACINE extended-release tablets, USP, 1 mg strength. The label shows a 100-tablet bottle package from Golden State Medical Supply, Inc. The label includes dosage form, a barcode, and storage instructions, noting child-resistant packaging and temperature guidelines. The product is marked as Rx Only and originates from Spain.*

FDA Label Image

51407-953-01ol (Guanfacine ER Tablets USP 2mg)

Label for GUANFACINE extended-release tablets, USP, 2 mg strength. The label includes drug name in yellow and black text, a blue box indicating 2 mg, and states it is for 100 tablets with prescription only. It shows the NDC 51407-953-01 and manufacturer Golden State Medical Supply, Inc., Camarillo, CA. Additional text details storage, child resistance, and dispensing instructions.*

FDA Label Image

51407-954-01ol (Guanfacine ER Tablets USP 3mg)

Label for GUANFACINE extended-release oral tablets, 3 mg strength, supplied in a 100-tablet package. Manufactured by Golden State Medical Supply, Inc. The label includes usage instructions, storage conditions, and states that the packaging is child-resistant. Barcodes and identifiers such as NDC 51407-954-01 are visible.*

FDA Label Image

51407-955-01ol (Guanfacine ER Tablets USP 4mg)

Label for GUANFACINE Extended-Release Tablets, USP 4 mg, by Golden State Medical Supply, Inc. The label includes NDC 51407-955-01, dosage form as tablets extended-release, and package quantity of 100 tablets. Directions note tablets should not be crushed or chewed. It also includes storage instructions and marketing information, stating the product is made in Spain.*

FDA Label Image

Figure2 (Guanfacine 2figure)

A horizontal error bar chart showing fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC. The chart compares the effects of various substances, including CYP3A4/5 inhibitors (Ketoconazole and Fluconazole), CYP3A4 inducers (Rifampin and Efavirenz), Oral Methylphenidate, and Lisdexamfetamine Dimesylate on the pharmacokinetics of guanfacine, with fold change values relative to a reference point shown on the x-axis.*

FDA Label Image

Figure 3 (Guanfacine 3 Figure)

A pharmacokinetic fold change chart showing the effects of oral methylphenidate and lisdexamfetamine dimesylate on the Cmax and AUC of guanfacine extended release tablets. The chart displays fold change and 90% confidence intervals relative to reference values on a horizontal axis ranging from 0 to 2.*

FDA Label Image

Figure1 (Guanfacine Figure 1)

A line graph comparing plasma concentration over 24 hours between extended-release guanfacine 1 mg QD and immediate-release guanfacine 1 mg QD. The y-axis shows guanfacine plasma concentration in ng/mL, and the x-axis shows time in hours. The graph demonstrates higher peak levels and faster decline for immediate-release compared to extended-release guanfacine.*

FDA Label Image

Figure 4 (Guanfacine Figure4)

A line graph comparing treatment failure rates over time (days) between a placebo group and an SPD503 treatment group. The x-axis shows time to treatment failure in days, and the y-axis shows the percentage of treatment failure. The placebo group shows a higher cumulative treatment failure rate over the 203-day period compared to the SPD503 group.*

FDA Label Image

Structure (Guanfacine Str)

Chemical structure diagram of guanfacine hydrochloride, showing its molecular skeleton with chlorine atoms and functional groups, representing the active ingredient guanfacine in hydrochloride salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.